Biblio Discovery — Demo Discovery Service

7 results for "Burcin Özdirik"

Showing 1–7 · 0.00 seconds · RSS

  1. Journal Article

    Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and ConceptsSummary

    Burcin Özdirik; Bernd Schnabl

    Cellular and Molecular Gastroenterology and Hepatology, Vol. 17 No. 3 · 2024 · English · DOAJ Scopus

    Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease with progressive biliary inflammation, destruction of the biliary tract, and fibrosis, resulting in liver cirrhosis and end-stage liver disease. To date, liver transplantation is the only definitive treatment option for PSC…

  2. Journal Article

    Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies

    Christoph Roderburg; Burcin Özdirik; Alexander Wree et al.

    Hepatic Oncology, Vol. 7 No. 2 · 2020 · English · DOAJ Scopus

    For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Different agents including checkpoint inhibitors, TKIs and anti-VEGFR antibodies demonstrated efficacy in treatment. For the first time, the combination of…

  3. Journal Article Full text

    Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors

    Teresa Hellberg; Raphael Mohr; Lukas Geisler et al.

    PLOS ONE, Vol. 15 No. 12 · 2020 · English · PLOS Scopus

    Background and aims: MicroRNAs (miRNAs) are profoundly involved into the pathophysiology of manifold cancers. Recent data suggested a pivotal role of miRNAs as biomarkers in different biological processes including carcinogenesis. However, their role in neuroendocrine tumors (NETs) is only poorly…

    Also available at: DOAJ

  4. Journal Article

    Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma

    Raphael Mohr; Fabian Jost-Brinkmann; Burcin Özdirik et al.

    Frontiers in Immunology, Vol. 12 · 2021 · English · DOAJ Scopus

    The implementation of immune checkpoint inhibitors (ICI) into the clinical management of different malignancies has largely changed our understanding of cancer treatment. After having proven efficacy in different tumor entities such as malignant melanoma and lung cancer, ICI were intensively tested…

  5. Journal Article Full text

    Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients

    Tobias Puengel; Beate Weber; Theresa H. Wirtz et al.

    Diagnostics, Vol. 12 No. 1 · 2021 · English · DOAJ Scopus

    Soluble receptor activator of nuclear factor κ B ligand (sRANKL) is a member of the tumor necrosis factor receptor superfamily, and therefore, involved in various inflammatory processes. The role of sRANKL in the course of bone remodeling via activation of osteoclasts as well as chronic disease…

  6. Journal Article

    Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice

    Fernanda Raya Tonetti; Hui Han; Marcos F. Fondevila et al.

    Gut Microbes, Vol. 18 No. 1 · 2026 · English · DOAJ Scopus

    Gastric acid-suppressive medications, particularly proton pump inhibitors (PPIs), are commonly used in patients with alcohol-associated liver disease (ALD) to prevent and manage upper gastrointestinal bleeding, gastroesophageal reflux disease, and non-steroidal anti-inflammatory/aspirin-induced…